A $25 billion biotech"s stock is popping on its promising cancer data (INCY)

Incyte, a $25 billion biotech company, debuted some new data about its cancer drugs on Wednesday, and the stock popped.  The drugmaker, which has one app.....»»

Category: topSource: businessinsiderMay 18th, 2017

AstraZeneca"s Lung Cancer Study Data Promising, Shares Spike

AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients. AstraZeneca, plc A.....»»

Category: worldSource: nytSep 11th, 2017

Why Cancer Biotech Clovis Oncology’s Stock Is Soaring

Impressive ovarian cancer drug data could make life hard for its rivals. Cancer-focused biotech Clovis Oncology’s stock spiked nearly 50% in early Monday trading after the company announced impressive clinical t.....»»

Category: europeSource: fortuneJun 19th, 2017

Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug

Focus this week remained on Biogen's (BIIB) first quarter results which surpassed expectations. Earnings season for the biotech sector is off to a promising start with Biogen BIIB report.....»»

Category: topSource: zacksApr 26th, 2017

Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising

While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate. Key updates in the biotech sector include a mixed quarter from Alexion ALXN and promising data on Celgene&r.....»»

Category: topSource: zacksFeb 22nd, 2017

Biotech Stock Roundup: Regeneron"s Praluent to Remain on Market for Now, GILD Presents HIV Data

Gilead (GILD) presented promising HIV data while Regeneron's PCSK9 inhibitor will remain on the market during the appeals process. Regeneron REGN got a bit of a boost w.....»»

Category: topSource: zacksFeb 15th, 2017

Bluebird Bio Flies; Blood Cancer Drug Impresses In Small Trial

Two biotech stocks are climbing today thanks to the results of one small drug trial testing a new type of treatment for multiple myeloma Bluebird bio (BLUE) surged more than 18% today after data from a Phase 1 study released late Wednesday showed that .....»»

Category: blogSource: barronsDec 1st, 2016

Tesaro: Priced for a Takeover?

Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that "M&A remains in focus" for Tesaro following the data.....»»

Category: blogSource: barronsOct 10th, 2016

Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow

Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow.....»»

Category: topSource: seekingalpha59 min. ago

Achillion shares drop as J&J to sell large stake

Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said .....»»

Category: topSource: marketwatchNov 14th, 2017

3 ETFs to Watch on Biotech Earnings

Major Biotech companies report mixed Q3 results. The earnings season is off to a flying start with equity markets scaling record highs, owing to a slew of upbeat economic data, strong corporate performance and President D.....»»

Category: smallbizSource: nytOct 29th, 2017

From shrimp shells to cancer cells: a biotech challenge

Global consortium applying chitosans in varied fields; UoH among participants.....»»

Category: topSource: thehindubusinesslineOct 27th, 2017

Why Celgene Corporation Tumbled Today

The biotech revised long-term guidance lower, but the growth prospects still look promising......»»

Category: topSource: foxnewsOct 26th, 2017

Short Sellers Chase Biotechs Higher

The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased......»»

Category: blogSource: 247wallstOct 25th, 2017

Biotech company aims to raise up to $22M in Austin"s next IPO; Cancer-fighting drug in advanced trials

Biotech IPOs have been pretty popular in Austin in recent years. The latest one comes from a company battling non-small cell lung cancer that intends to price its offering at $5 a share......»»

Category: topSource: bizjournalsOct 24th, 2017

32 Stocks Moving In Wednesday"s Mid-Day Session

Gainers Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) surged 45.09 percent to $20.98. Spectrum Pharmaceuticals highlighted poziotinib data in NSCLC at 18th IASLC World Conference on lung cancer in Japan. read more.....»»

Category: blogSource: benzingaOct 18th, 2017

Why Spectrum Pharmaceuticals Shares Are Surging

Spectrum Pharmaceuticals saw its shares make a solid gain early on Wednesday after the firm announced interim data from its mid-stage trial for the treatment of non-small cell lung cancer......»»

Category: blogSource: 247wallstOct 18th, 2017

New cancer drugs boost Johnson & Johnson"s estimates

Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast, driven by strong demand for its new cancer drugs and gains from its acquisition of Swiss biotech Actelion......»»

Category: topSource: moneycentralOct 17th, 2017

Strong drug sales, Actelion buy power J&J"s profit beat

(Reuters) - Johnson & Johnson reported a higher-than-expected quarterly profit and raised its full-year forecast, driven by strong demand for its new cancer drugs and gains from its acquisition of Swiss biotech Actelion......»»

Category: topSource: reutersOct 17th, 2017

Mass. biotech jobs hit all-time high as drug pipeline swells

Massachusetts is in the midst of a drug research and development boom — and industry trade group MassBio has the jobs numbers and pipeline data to prove it. MassBio released its annual “snapshot” report on Tuesday outlining some of the major trends.....»»

Category: topSource: bizjournalsOct 17th, 2017